全文获取类型
收费全文 | 3790篇 |
免费 | 501篇 |
国内免费 | 59篇 |
学科分类
医药卫生 | 4350篇 |
出版年
2024年 | 4篇 |
2023年 | 114篇 |
2022年 | 91篇 |
2021年 | 188篇 |
2020年 | 247篇 |
2019年 | 204篇 |
2018年 | 167篇 |
2017年 | 183篇 |
2016年 | 167篇 |
2015年 | 133篇 |
2014年 | 238篇 |
2013年 | 300篇 |
2012年 | 163篇 |
2011年 | 167篇 |
2010年 | 202篇 |
2009年 | 193篇 |
2008年 | 182篇 |
2007年 | 164篇 |
2006年 | 174篇 |
2005年 | 144篇 |
2004年 | 140篇 |
2003年 | 140篇 |
2002年 | 101篇 |
2001年 | 92篇 |
2000年 | 76篇 |
1999年 | 70篇 |
1998年 | 34篇 |
1997年 | 38篇 |
1996年 | 30篇 |
1995年 | 36篇 |
1994年 | 24篇 |
1993年 | 21篇 |
1992年 | 17篇 |
1991年 | 10篇 |
1990年 | 15篇 |
1989年 | 11篇 |
1988年 | 15篇 |
1987年 | 13篇 |
1986年 | 7篇 |
1985年 | 4篇 |
1984年 | 12篇 |
1983年 | 3篇 |
1982年 | 6篇 |
1981年 | 4篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1973年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有4350条查询结果,搜索用时 31 毫秒
81.
82.
Marta Bertolin‐Colilla MD Rebeca Alcalá MD Gustavo Deza MD Luciano Polino MD Fernando Gallardo MD PhD Ramon M. Pujol MD PhD 《Pediatric dermatology》2018,35(5):e291-e293
Inflammatory linear verrucous epidermal nevus and linear psoriasis are different entities with clinical and histopathologic similarities. Isolated reports of inflammatory linear verrucous epidermal nevus with concomitant psoriasis or a positive family history of psoriasis have been described, and the possibility that inflammatory linear verrucous epidermal nevus may be a mosaic form of cutaneous psoriasis has been postulated. We report a 17‐year‐old boy with a congenital, linear, erythematous, keratotic plaque on the dorsum of the fifth finger of the left hand with ipsilateral nail dystrophy. Histopathologic examination showed epidermal hyperplasia with alternating orthokeratosis and parakeratosis. During follow‐up, he developed erosive monoarthritis of the distal interphalangeal joint. This case seems to confirm the association between inflammatory linear verrucous epidermal nevus and arthritis and supports a possible relationship between inflammatory linear verrucous epidermal nevus and psoriasis. 相似文献
83.
84.
Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis with an IL‐36RN deficiency treated with infliximab: Case report and review of the literature 下载免费PDF全文
Sebastian Podlipnik Lorena de la Mora Mercè Alsina José M Mascaró Jr 《The Australasian journal of dermatology》2017,58(2):e44-e47
Pneumocystis jirovecii pneumonia (PCP) is a relatively rare complication in non‐HIV patients receiving immunosuppressive treatment. Since the introduction of tumour necrosis factor‐α inhibitors cases of this complication have increased. We report the case of a 54‐year‐old, HIV‐negative patient, who presented to our department with a long history of pustular psoriasis with poor response to traditional treatments. During the last admission he developed a severe flare that was unresponsive to cyclosporine, therefore infliximab was initiated. After the third dose he developed PCP that required admission to the intensive care unit, with a positive response to i.v. administration of trimethoprim/sulfamethoxazole. During follow up a mutation in the IL36RN gene compatible with an IL‐36RN deficiency was found and anakinra was started, with rapid improvement of his psoriasis. PCP is a severe complication in patients receiving immunosuppressive therapy and is probably underreported by dermatologists. There are no clinical guidelines for PCP prophylaxis in dermatological patients who will receive immunosuppressive or biological treatments. We believe that it is necessary to report the cases of PCP to assess the real impact of this complication and develop appropriate prophylaxis guidelines. 相似文献
85.
April W. Armstrong Michael P. Siegel Jerry Bagel Erin E. Boh Megan Buell Kevin D. Cooper Kristina Callis Duffin Lawrence F. Eichenfield Amit Garg Joel M. Gelfand Alice B. Gottlieb John Y.M. Koo Neil J. Korman Gerald G. Krueger Mark G. Lebwohl Craig L. Leonardi Arthur M. Mandelin M. Alan Menter Abby S. Van Voorhees 《Journal of the American Academy of Dermatology》2017,76(2):290-298
86.
87.
Min‐Geol Lee Yu‐Huei Huang Joo‐Heung Lee Seung‐Chul Lee Tae‐Gyun Kim Derrick Chen‐Wee Aw Weibin Bao Cathleen Michelle A. Dee Adriana Guana Tsen‐Fang Tsai 《The Journal of dermatology》2019,46(9):752-758
The 52‐week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient‐reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double‐blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis. 相似文献
88.
C. Hagert R. Siitonen X.-G. Li H. Liljenbäck A. Roivainen R. Holmdahl 《Clinical and experimental immunology》2019,196(3):383-391
Psoriasis (Ps), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are common diseases dependent on environmental factors that activate the immune system in unknown ways. Mannan is a group of polysaccharides common in the environment; they are potentially pathogenic, because at least some of them induce Ps-, PsA- and RA-like inflammation in mice. Here, we used positron emission tomography/computed tomography to examine in-vivo transport and spread of mannan labelled with fluorine-18 [18F]. The results showed that mannan was transported to joints (knee) and bone marrow (tibia) of mice within 6 h after intraperitoneal injection. The time it took to transport mannan, and its presence in blood, indicated cellular transport of mannan within the circulatory system. In addition, mannan was filtered mainly through the spleen and liver. [18F]fluoromannan was excreted via kidneys, small intestine and, to some extent, the mouth. In conclusion, mannan reaches joints rapidly after injection, which may explain why mannan-induced inflammatory disease is targeted to these tissues. 相似文献
89.
90.
Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients
《Modern rheumatology / the Japan Rheumatism Association》2013,23(5):738-742
AbstractObjectives New adverse events are being reported with the increased use of anti-tumor necrosis factor (TNF) α therapy. We studied cases of anti-TNFα-induced psoriasis observed in our pool of 514 patients receiving anti-TNFα treatment in Turkey.Methods Three rheumatoid arthritis patients and 3 ankylosing spondylitis patients with anti-TNFα-induced psoriasis were included in the study. All patients were examined by a dermatologist, and 3 patients underwent skin biopsy.Results None of the 6 patients had preexisting psoriasis or a familial history of psoriasis. The earliest and latest occurrences of psoriatic lesions were at the 6th week and 44th month of anti-TNFα therapy, respectively. Psoriasis was severe and refractory in two patients (requiring systemic treatment), while it presented as mild in four patients. Anti-TNFα therapy was totally withdrawn in case 1. In case 2, the treatment was halted for 3 months then switched to another TNFα blocker, and case 3 was switched to another anti-TNFα treatment. The treatment was sustained in the other 3 patients (cases 4, 5, and 6).Conclusions TNFα blockers are very effective agents in the treatment of psoriasis, but it is interesting that the same molecules can, paradoxically, induce psoriasis. The occurrence of anti-TNFα-induced psoriasis in six out of 514 patients suggests that the incidence of this adverse reaction is, in fact, as not low as presumed in the literature. In some cases, a severe course of psoriasis may limit the use of these agents. 相似文献